Shares in CV Therapeutics (nasdaq: CVTX - news - people ) rose more than $1, or 4%, to $26.25 in pre-market trading today. A decision from the Food and Drug Administration is expected by Monday on the biotech's angina treatment Ranexa.
The heart drug has been through six years of hurdles, and recently helped patients whose symptoms weren't being controlled even at top doses of high-blood pressure drug Norvasc from Pfizer (nyse: PFE - news - people ). A big question will be whether the FDA's label restricts Ranexa's use to that small patient population, or leaves doctors open to prescribe it to a broader market.